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Abstract
The tumor microenvironment is comprised of cancer cells and their surround-
ings, including various normal cells and non-cellular components, and each tumor 
tissue has a distinctive microenvironment. Cancer progression is affected by dif-
ferent microenvironmental states, such as the heterogeneity of infiltrating immune 
cells. Therefore, it is necessary to understand the complex cell-to-cell interactions 
associated with tumor developmental stages in different tissues. Recent revolution 
of single-cell RNA sequencing technology can uncover the tumor microenviron-
ment diversity. We have developed a novel strategy of single-cell transcriptome 
analysis: next generation 1-cell sequencing (Nx1-seq) technology, and it allows for 
profiling of thousands of single cells from tumor tissue. Our microwell with cell 
bar-code beads device can detect genes with high sensitivity, and it is easily trans-
ported anywhere without any other dedicated devices. Further, the developmental 
cost is relatively cheaper than other single-cell RNA sequencing methods. In this 
study, we introduce representative application of the single-cell RNA sequencing 
technique in gynecological cancers, and we show the result of Nx1-seq application 
in human endometrioid adenocarcinoma tissue.
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1. Introduction
Tumor tissues are aggregates of various cell populations, and each single cell 
or cell population plays an important role for cancer progression and regres-
sion. The representative cell populations of the tumor microenvironment are 
cancer cells, surrounding normal cells, and infiltrated immune cells of all types. 
Anticancer agents and immune checkpoint blockers, such as programmed death 
receptor-1 (PD-1) and its ligand, have been widely used in patients, and the cura-
tive effect is great. However, for many patients, these treatments are ineffective 
because the minor cell populations escape the immune system. Therefore, a deeper 
understanding of the tumor microenvironment immunology will be critical for 
immunotherapy to become a standard therapy. In addition, it is important to clarify 
patient and tumor-dependent cell phenotypes by gene expression analysis because 
the composition and functions of the tumor microenvironment are heterogeneous 
between cancers and patients.
Previous gene expression measurements have been performed on bulk samples. 
Conventional bulk-based RNA sequencing or microarrays alone or in combination 
with flow cytometry can provide a full view of all gene expression, and it is useful to 
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investigate the tumor microenvironment. However, a blended gene expression analy-
sis might mask the minor cell population, which may be the origin of tumor progres-
sion. To overcome this problem, RNA sequencing methods that can analyze mRNA 
expression at the single-cell level from thousands of individual cells are required. The 
fundamentally necessary approaches of single-cell RNA sequencing are: (1) single-
cell isolation with a high survival rate, (2) cell lysis to obtain mRNA, (3) conversion 
of mRNA into cDNA, (4) specific amplification of cDNA, (5) cDNA fragmentation 
process, and (6) creation of high-quality sequencing libraries. After single-cell isola-
tion, there are some innovate single-cell transcriptome analysis methods (e.g., CEL-
seq [1], Quartz-seq [2], Quartz-seq2 [3], Smart-seq [4], Drop-seq [5], iDrop RNA 
sequencing [6], Cyto-Seq [7], automated microwell-based RNA sequencing [8], and 
our next generation 1-cell sequencing; Nx1-seq [9]), and every method uses oligo-dT 
primers containing cell-specific bar-codes, which tag cDNA from single cells.
Although cell number, tissue volume analyzed, analysis sensitivity, and overall 
cost for creating libraries are completely different, any methods with an efficient 
data analysis procedure would be particularly useful to understand cellular 
heterogeneity and to identify rare cell populations. For example, six prominent 
single-cell RNA sequencing methods: CEL-seq2, Drop-seq, MARS-seq, SCRB-seq, 
Smart-seq, and Smart-seq2 have been compared in mouse embryonic stem cells 
[10]. If single-cell transcriptome analysis were performed in a limited number of 
cells or small tissue volume, SCREB-seq and MARS-seq will have better sensitivity. 
Yet, Smart-seq2 may detect the highest number of genes per cell with amplification 
noise. Drop-seq is a preferable and more cost-effective method for large numbers of 
cells with low sequencing depth. In terms of the number of reads per cell and genes, 
we also compared our Nx1-seq and Drop-seq, and it revealed similar sensitivity [9]. 
Recently, another microwell-based RNA sequencing has been developed [11], and 
this is a simple, high-throughput, and low-cost device. The principle of their device 
is similar to Cyto-Seq and Nx1-seq, but the differences are the beads material and 
the loading order of single cells and beads to the microwell. They have attempted 
to construct a “mouse cell atlas” by using over 50 mouse tissues, organs, and cell 
cultures. One of the reasons they can analyze a large sample amount is the low-cost 
device without any expensive, exclusive apparatus and kits for capturing mRNA 
from a single cell. Previously, a detailed description of each method was thoroughly 
reviewed [12]; yet, innovate new technologies for single-cell RNA sequencing are 
still to be developed. We also continue improving our Nx1-seq device progressively.
2. Single-cell transcriptome analysis for cancer tissues
To find new molecular targets for a cancer prognosis prediction method, it 
requires an understanding of the single-cell level transcriptome heterogeneity in 
tumor tissues and their microenvironment. Bulk-based RNA sequencing may also 
contribute to development of new minimally invasive monitoring of circulating 
tumor cells or cancer gene-transferred macrophages and lymphoid cells. If the 
targeted cancer antigen and/or cell surface protein were held in small cell popula-
tions, the intensity signal of the gene expression would be weak. In this case, single 
cell transcriptome analysis is a useful tool to identify the small cell population 
and obtain all of the gene information in this population. In the next chapter, we 
describe our Nx1-seq methods in detail and show a representative Nx1-seq applica-
tion in human endometrioid adenocarcinoma tissue. At this time, there are no 
reports about single-cell transcriptome analysis for endometrioid adenocarcinoma, 
except our research [9]. Here, we briefly summarize recent applications of single-
cell RNA sequencing in one of the major gynecological cancers, breast cancer.
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Chung et al. conducted single-cell transcriptome analysis for 11 primary tumors 
and 2 metastatic lymph nodes from 11 patients, representing 4 breast cancer sub-
types [13]. It clearly displayed the carcinoma and tumor-infiltrating immune cells 
population using the 10–17 μm integrated fluidic circuit mRNA sequencing chip 
in the C1™ Single-Cell Auto Prep System of Fluidigm®. The C1™ integrate fluidic 
circuit is an integrated microfluidic system that can automatically isolate individual 
cells from suspended cells. Subsequently, cell lysis buffer is automatically applied to 
individual cells to capture mRNA. It takes 5 h to make sequence-ready libraries from 
isolated cells, and the operation is simple [14]. The authors demonstrated that many 
T cells with high cytokine and chemokine expression were observed in three triple 
negative breast cancers (TNBC), and their phenotypes were regulatory T cells (two 
out of three patients) and another one was exhaustion and cytotoxicity signatures 
[13]. This result indicates that immune checkpoint blockers may be effective in the 
patient.
Recently, single-cell transcriptome analysis using 10X Genomics Chromium 
was reported in breast cancer [15, 16]. Cazet et al. investigated the anti-tumor 
inhibitor effects in a mouse tumor model, in terms of changes in the gene expres-
sion profiles of each cell population [15]. Tumor development and progression 
were associated with stiffness of the extracellular matrix, and collagen density 
in the tumor-stromal interface was reduced by small molecule inhibitor of 
smoothened (SMO) treatment. They also showed that the chemotherapy signifi-
cantly slowed tumor growth and reduced the frequency of metastatic disease 
in xenograft models of human TNBC. In another article, an infiltrating T cell 
population in breast cancer was classified from 123 patients, and it demonstrated 
the importance of qualitative identification of CD8+ T cell subtypes [16]. CD8+ 
CD103+ T cells contained features of read tissue-resident memory, including high 
granzyme B, PD-1, and cytotoxic T lymphocyte (associated) antigen 4 (CTLA-4), 
rather than CD8+ CD103− T cells, meaning that these are target cells for immune 
checkpoint brokers.
The above representative reports using single-cell read transcriptome analysis 
were well analyzed, but we speculate that the cost for creating a sequence library 
per sample using commercially available device-dependent kits may be expensive. 
Many samples should be analyzed in a clinical study because the observed microen-
vironment heterogeneity is patient-, malignant-, or organ-dependent. In addition, 
if characterization of tumor gene expression profiling was recognized according 
to the individual’s region or country, it should be performed locally because fresh 
samples, not frozen ones, are better to analyze for RNA sequencing. From this 
standpoint, a device with low-cost, in high sensitivity, and easy performance is 
recommended.
3. Nx1-seq
The major component of Nx1-seq (next generation 1-cell sequencing) consists 
of bar-code beads and a specifically processed microwell. In this chapter, we 
describe these devices in further detail.
3.1 Bar-code beads
Oligonucleotides on beads have the following sequence: (1) “root array” is 
used as a priming site for subsequent PCR; (2) “cell bar-code” allocates 12 bp of 
oligonucleotide to identify cells, and the bar-code has 412 = 16,777,216 various 
patterns; (3) “UMI” (a unique molecular identifier) has 8 bp of oligonucleotide to 
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eliminate gene duplication bias and improve signal/noise ratio by PCR, meaning 
that 1-cell bar-code has 1 UMI; and (4) “poly-dT” array consists of 25 bp oligo dT 
sequences for capturing polyadenylated mRNA. The bar-code beads (“root”-“cell 
bar-code”-“UMI”-“poly-dT”) were made by following a modified instruction 
manual for the GS Junior Titanium emulsion PCR Kit (Lib-L) from Roche® 
Applied Science or synthesized by ChemGenes Corporation (Wilmington, MA, 
USA) with additional annealing and ligation of the poly-dT array in our labora-
tory. The detailed method for generating bar-code beads using the emulsion PCR 
kit is described in our previous report [9]. We could get randomly synthesized 
various “cell bar-code” inserted bar-code beads, and the beads were washed with 
Low TE buffer (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA pH 8.0) and stored at 
−20°C until use.
3.2 Microwell slide
The microwell plate was prepared using polydimethylsiloxane (PDMS) and 
was cut 2 × 2 × 2 cm using cutting dies (Noda Co. Ltd., Osaka, Japan) which con-
tained 1.3−1.6 × 105 microwells. The size of one microwell was 25 ± 3 μm diameter, 
40 ± 8 μm height, 20 ± 9 ρL capacity (column-shape), and the distance between 
microwells was 5 μm (YODAKA CO., Ltd., Kanagawa, Japan). If the size of the 
target cell was not between 15 and 25 μm, the diameter and height sizes were easily 
adjusted. The PDSM microwell plate was placed in an oxygen plasma chamber for 
hydrophilic processing because PDMS is a hydrophobic material. The microwell 
plate was quickly set into the Nunc™ Lab-Tek™ Chamber slide system (Thermo 
Fisher Scientific, Waltham, MA, USA), and bar-code beads were applied to the 
microwell plate. If the expected number of cells obtained from the tumor tissue 
was <1 × 105 cells, the PDMS microwell was cut ~1/4 or 1/2 of its size and set into 
the appropriate Nunc™ Lab-Tek™ Chamber slide system (Figure 1). The PDMS 
microwell plate was kept at 4°C, meaning that the Nx1-seq device can be stored 
until use.
Figure 1. 
Schematic drawings of Nx1-seq. Cell bar-code beads (see the structure of cell bar-code bead) were filled into 
microwells, and an adequate number of single cells was applied. Cells were dissolved in lysis buffer, and mRNA 
from the cell was captured by cell bar-code beads in each microwell. After cellular lysis, all beads were collected 
into a single tube. Images of the microwell plate show that our device had some variations for differences of the 
number of applied cells.
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3.3 Lysis of cells
After single cell isolation, ~1−2 × 105 cells mixed with 3.7 mL of cold PBS were 
applied to PDMS microwell plate (2 × 2 × 2 cm) and put the cover without enter-
ing a bubble. The microwell plate was put on ice for 10–15 min, which let the cells 
settle into the microwell by gravity. About 5% of whole microwells were filled 
with single cells according to Poisson distribution. The solution was removed from 
the microwell plate, and 1 mL of fresh cold PBS was gently applied. The washing 
process was repeated by 3–4 times. The reagent composition of 1 mL of cell lysis 
buffer was; 2 mg of N-Lauroylsarcosine sodium salt, 200 μL of 1 M Tris-HCl pH 7.5, 
40 μL of 0.5 M EDTA pH 8.0, 750 μL of deionized water, 50 μL of 1 M dithioth-
reitol solution. The microwell plate was put on a microscopy, and we found the 
microwell which contains only cell without bar-code bead, then PBS was removed 
and 1 mL of cell lysis buffer was gently applied from the corner of the microwell. 
Most cells were getting to dissolve within 1–3 min, but it kept for 8 min. The cell 
lysis buffer was removed carefully and washing buffer (200 mM Tris-HCl pH 7.5, 
20 mM EDTA, 50 mM DTT, 0.2% N-Lauroylsarcosine sodium salt, 2% Ficoll) was 
added. Conversion of mRNA into cDNA was done by SuperScript™ II or IV Reverse 
Transcriptase (Thermo Fisher Scientific).
4.  Nx1-seq application to human endometrioid adenocarcinoma  
tissues
Previously, we reported the application of Nx1-seq to human endometrioid 
adenocarcinoma (EA) tissues [9]. Here, we summarize the result shortly. EA tissues 
were removed from the myometrial infiltration side (M-side) and endometrial side 
(E-side). Myometrial invasion is an independent prognostic parameter of EA, and 
invasion is correlated with the risk of metastasis to the lymph nodes. Single-cell 
analysis in each side revealed that EA had six cancer (cluster #0, 1, 2, 3, 5, 6), two 
macrophage (#4, 8), and one T cell population (#7) (Figure 2A). To analyze the 
sequencing data, we used Seurat software (http://satijalab.org/seurat/), which is 
an open tool for analyzing single-cell genomics in R (http://www.R-project.org/). 
As shown in Figure 2B, the distribution of cancer cells on the E-side and M-side 
differed, and the majority of the macrophage cluster (#4) was on the M-side. The 
number of infiltrating macrophages was not different between sides (Figure 2C), 
but macrophage specificity was more cytotoxic T lymphocytes (CTL)-like on the 
M-side. Macrophages on the M-side had higher expression of inflammatory che-
mokines, C-X-C motif chemokine ligand 3 and 8 (CXCL3 and CXCL8) and NF-κ-B 
inhibitorα (NFKBIA) (Figure 2D). The proportion of macrophages expressing 
the inflammatory factors CCL5, IL10 and IL6 did not differ among the two sides 
(data not shown). It has been widely believed that many cells expressing some 
malignancy-related genes exist on the M-side; however, our previous result showed 
that cancer cells on the E-side were highly malignant when compared to those on 
the M-side.
In addition, a cancer stem-like cell population was also higher on the E-side 
(e.g., the ratio of SOX2+ cells on E-side vs. M-side was 17 vs. 6%, respectively) [9]. 
These data reveal that cells with high malignant potential (HMP) are present at the 
same site of cancer tissue (E-side) in EA. To confirm our hypothesis, we focused 
on the ubiquitin C-terminal hydrolase L1 (UCHL1) gene. Protein ubiquitination or 
de-ubiquitination regulates cell growth, differentiation, transcription, and tumor 
prognosis. The function of UCHL1 in neurodegenerative disorders, particularly 
in Alzheimer’s disease and Parkinson’s disease has been reported, and decreased 
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hydrolase activity and UCHIL1 ligase activity may affect the neurodegeneration 
[17, 18]. In our EA tissue, the relative intensity of UCHL1 expression was higher on 
the E-side (Figure 2E). The functional role of UCHL1 in human tumor malignancy 
is still unresolved, but this gene has been reported to be cancer-related in endome-
trial cancer patients [19]. Goto et al. demonstrated that activation of UCHL1 via 
hypoxia inducible factor-1 (HIF-1) is the key regulator for underling mechanism of 
tumor metastasis, and they expected UCHL1 is as prognostic marker and treatment 
target for breast and lung cancers [20].
From the enormous single-cell RNA-sequencing data, the researcher must 
determine to manage and understand the functional meaning of the cell popula-
tion. In particular, understanding how the gene is related to overall survival of EA 
patients in the clinical site is useful. Hence, we used the “cBioPortal For CANCER 
Figure 2. 
Clustering of human endometrioid adenocarcinoma tissue. (A) Nine clusters were identified by t-SNE analysis. 
(B) Cluster analysis in each side; sky blue dots indicate the endometrial side (E-side) and red dots are the 
myometrial infiltration side (M-side). (C) The ratio (%) of macrophages in the E- or M-side of tissues is 
shown. (D) Relative intensity of CXCL3, CXCL8, and NFKBIA in both sides. *p < 0.001 for E-side vs. M-side 
by the Mann-Whitney U-test. (E) Summary of UCHL1 expression. Relative intensity of UCHL1 is shown, and 
*p < 0.001 for E-side vs. M-side by the Mann-Whitney U-test. (F) Overall survival of Kaplan-Meier estimate 
was obtained from cBioPortal for CANCER GENOMICS. Blue: control, Red: relatively higher expression 
group. *p < 0.001 for the control vs. high UCHL1 expression.
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GENOMICS” website and chose “Uterine Corpus Endometrial Carcinoma (EC) 
(TCGA, Provisional).” Subsequently, we set “Genomic profiles” as “mRNA 
Expression,” and chose “mRNA Expression z-Score (microarray),” then input 
the gene name “UCHL1” (http://www.cbioportal.org/). Overall Survival of 
Kaplan-Meier (K-M) Estimate showed that high UCHL1 expression in endometrial 
carcinoma patients significantly decreased survival time (Figure 2F). The median 
months survival in the UCHL1 high group was 48.75 months. The log-rank p value 
for K-M analysis for correlation between mRNA expression level and patient 
survival was 1.965 × 10−4. The Overall Survival of K-M Estimate was not calculated 
from the EA but EC dataset, however EA of the endometrium is the most common 
type of EC [21]. Therefore, the result indicates that higher expression of UCHL1 
on the E-side somehow affects EA progression, and it supports our hypothesis that 
cells with HMP are present on the E-side. Whether we chose other data set “Uterine 
Corpus Endometrial Carcinoma (TCGA, Nature 2013),” the result of Overall 
Survival of K-M Estimate was also significant (p = 1.06 × 10−3). The median months 
of disease-free in high UCHL1 patients was 12.94 months, and it was significantly 
earlier by the Disease/Progression-free Kaplan-Meier Estimate. However, the 
significant correlation was not observed if we chose “mRNA Expression z-Scores 
(RNA Seq V2 RSEM), z-score threshold ± 2.0” (p = 0.955). There was other use-
ful database to realize the overall survival of EC patients. We used the “THE 
HUMAN PROTEIN ATLAS” website and input the gene name “UCHL1,” then set 
“PATHOLOGY ATLAS” (http://www.proteinatlas.org/). The prognostic summary 
highlighted that UCHL1 was the candidate as the prognostic marker in EC. The 
5-year survival in the UCHL1 high or low group was 66 or 86% respectively, and the 
p score was 4.1 × 10−5 from the total of 541 female patients.
As shown in Figure 3, there was significant differences about UCHL1 expres-
sion between each side, and immunostaining of UCHL1 showed a similar staining 
Figure 3. 
Immunohistochemistry of UCHL1 in E-side and M-side. Macrophages identified by pathologist are also 
positively stained. Red allows shows macrophage. The scale bar indicates 30 μm.
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pattern in macrophages as well as cancer cells. Also, UCHL1 staining in E-side was 
relatively higher. These data indicate that microenvironment of tumor tissue might 
affect the gene properties of immune cells, and gene expression pattern might 
resemble closely to cancer cells.
The high expression of CXCL3 was not related to the prognosis of EA (p = 0.987) 
by the CANCER GENOMICS, but CXCL3 high group significantly improved 
5-year overall survival by the PROTEIN ATLAS. At this moment, there was only 
one patient whose expression of CXCL8 was high in the CANCER GENOMICS, 
but 5-year survival of CXCL8 high or low group in EC patients was 79 or 70% 
respectively, and there was no significant difference. In contrast, higher expression 
of NFKBIA significantly decreased survival time by “mRNA Expression z-Sore 
(microarray)” (p = 0.0246), but not “mRNA Expression z-Score (RNA Seq V2 
RSEM)” by the CANCER GENOMICS. In contrast, the 5-year overall survival in 
the PROTEIN ATLAS was not significant. These results indicate that the researcher 
must use some database to understand how the target genes are related to the 
prognosis of cancers. Further studies for other HMP-related genes are ongoing in 
our laboratory.
5. Conclusion
Single-cell sequencing is believed to be a powerful tool to answer unknown 
biological questions, and researchers may have many expectations to find new 
insights of their hypotheses. Indeed, bulk-based RNA sequencing is averaged across 
a cell population, but the method to obtain total RNA is relatively simple and easy. 
Most importantly, we can detect gene expression profiling of the whole tissue. Of 
course, as mentioned above, the existence of minor cell populations, such as cancer 
stem-like cells, may not be detected in bulk-based RNA sequencing data. If the 
researchers knew the biomarkers of targeted cells in small population, the gene can 
be detected from the bulk-based RNA sequencing data. But it is unknown which 
cell expresses and how many cells have the targeted gene because of the averaged 
data by bulk-based RNA sequencing. Thus, it is better to ponder over which method 
is aimed at the biological question before choosing more difficult and expensive 
single-cell RNA sequencing.
Current protocols of dispersing single cells in each tissue are not optimized 
worldwide; therefore, some cells or cell populations may disappear in the course 
of isolating single cells from tumor tissue. One of the most important procedures 
for single-cell RNA sequencing is isolation of single cells from tumor tissues. 
Mechanical and/or enzymatic cell distributed processes followed by fluorescence-
activated cell sorting (FACS), magnetic-activated cell sorting (MACS), or density-
gradient method are the current standard [22], but the softness or hardness of 
tissues differs depending on the tumor. Inappropriate single-cell isolation methods 
are biased; therefore, more detailed studies are needed to optimize isolation of 
single cells for each tissue.
Nonetheless, single-cell sequencing is a great tool for detecting heterogeneous 
subpopulations, cell-to-cell communication, and spatial interactions. Moreover, the 
many gene expression changes by carcinostatic agents can be monitored. To ana-
lyze extensively heterogeneous clinical samples, highly sensitive, low cost, quick, 
and simple technologies to capture mRNA from a single cell are required. Our 
newly developed single-cell transcriptome analysis, Nx1-seq, can be a useful tool 
to understand tumor microenvironments with high sensitivity and low cost. This 
new approach is a simple method, and it can be used to analyze several hundreds 
to tens of thousands of cells without specialized equipment. Further, it is easy to 
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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change the size of the microwell for larger or smaller cells. Furthermore, microwells 
equipped with bar-code beads in the Nunc™ Lab-Tek™ Chamber slide system can 
be stored for several months before use. Nx1-seq is a powerful approach for char-
acterizing cellular diversity under physiological and pathological conditions. The 
combined analysis of t-SNE by Seurat and detailed gene profiling can discover new 
tumor biomarkers or new target genes for regression of tumor tissues. We continue 
to develop better Nx1-seq devices to satisfy requests from researchers. It is about 
continued learning on a daily basis.
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